FDA approves Keytruda for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma HNSCC Keytruda was approved for use in combination with platinum and fluorouracil FU for all patients and as a s [...]
The US Food and Drug Administration granted accelerated approval to Polivy polatuzumab vedotin-piiq in combination with the chemotherapy Treanda bendamustine and Rituxan rituximab product a combination known as 8220BR8221 to treat adult patients with diff [...]
A UCLA-led research team has pinpointed a three-drug combination that could prove to be an effective new therapy for people with a specific type of advanced melanoma The approach shows promise for extending the lives of people with a type of melanoma that [...]
An immunotherapy drug could prove just as effective as chemotherapy in prolonging the lives of patients with advanced cancers of the stomach or food pipe For some the immune-boosting treatment offered improved survival compared to standard treatment The i [...]
After 3 years 80 of men with metastatic hormone-sensitive prostate cancer who received enzalutamide along with testosterone suppression were alive compared to 72 of men who received standard care Chicago 8211 Enzalutamide an oral androgen receptor inhibit [...]
More than 32000 cancer experts from around the world will gather to share the latest clinical cancer research impacting patient care at the 55th Annual Meeting of the American Society of Clinical Oncology ASCO May 31-June 4 in Chicago Advances in precisio [...]
On May 28 2019 the Food and Drug Administration approved lenalidomide REVLIMID Celgene Corp in combination with a rituximab product for previously treated follicular lymphoma FL and previously treated marginal zone lymphoma MZL The MAGNIFY clinical trial [...]
The US Food and Drug Administration FDA has approved Piqrayalpelisib formerly BYL719 in combination with fulvestrant for the treatment of postmenopausal women and men with hormone receptor positive human epidermal growth factor receptor-2 negative HRHER2- [...]
An interim analyses of the phase 3 ASCEND clinical trial evaluating single-agent Calquence acalabrutinib compared to Rituxan rituximab plus idelasib or bendamustine in recurrent chronic lymphocytic leukemia CLL is closed early due to favorable results 1 A [...]
Zytig Abiraterone acetate plus prednisone and androgen deprivation therapy ADT significantly extends overall survival compared with placebo plus ADT in men with newly diagnosed high-risk metastatic castration-sensitive prostate cancer CSPC About Zytig Zyt [...]
